莫桑比克出现贝达喹啉耐药结核及Xpert MTB/RIF未检出的rpoB Ile491Phe突变耐多药和广泛耐药结核分枝杆菌菌株:一项回顾性观察研究
该回顾性观察研究对2015—2021年莫桑比克马普托国家结核参比实验室704株耐利福平结核分枝杆菌复合群菌株进行全基因组测序。628株(89%)为耐多药,其中146株(23%)为pre-XDR,24株(4%)为XDR;61株(9%)对贝达喹啉耐药,耐药率从2016年3%升至2021年14%。31株(4%)携带rpoB Ile491Phe突变(Xpert MTB/RIF无法检出),其中23株(74%)同时耐贝达喹啉。
要点
- 莫桑比克耐多药菌株中pre-XDR和贝达喹啉耐药均高度流行,贝达喹啉耐药率从2016年3%升至2021年14%。
- 31株(4%)携带rpoB Ile491Phe突变,Xpert MTB/RIF无法检出,其中23株(74%)同时耐贝达喹啉。
- Ile491Phe突变株占耐多药且耐贝达喹啉菌株的31%(n=10)和XDR菌株的54%(n=13)。
核心结论
- 莫桑比克耐多药结核分枝杆菌复合群菌株中pre-XDR和贝达喹啉耐药均高度流行,贝达喹啉耐药频率随时间增至四倍,且可见于无氟喹诺酮耐药的菌株。
- Ile491Phe突变株常见,占耐多药且耐贝达喹啉菌株的31%(n=10)和XDR菌株的54%(n=13)。
- 基于现有诊断流程和治疗方案,Ile491Phe所致利福平耐药和贝达喹啉耐药的出现可能危及耐多药结核的预防和诊疗,除非推广测序技术。
- 诊断逃逸菌株的潜在跨境传播需进一步研究。
研究设计与样本
- 回顾性观察研究,对2015年至2021年提交至莫桑比克马普托国家结核参比实验室的704株耐利福平结核分枝杆菌复合群菌株进行全基因组测序。
- 进行了系统发育菌株分类、基因组耐药预测和聚类分析。
主要发现
- 2015年1月1日至2021年7月31日,国家结核参比实验室生物样本库共鉴定2606株异烟肼或利福平耐药结核分枝杆菌复合群分离株,其中1483株(56.9%)来自男性,1114株(42.7%)来自女性,9株(0.4%)性别未知。
- 基于基因组的耐药预测将704株结核分枝杆菌复合群菌株分类为耐利福平;628株(89%)为耐多药,其中146株(23%)为pre-XDR(额外氟喹诺酮耐药),24株(4%)为XDR(氟喹诺酮和贝达喹啉联合耐药)。
- 704株中61株(9%)对贝达喹啉耐药:76株耐利福平且耐贝达喹啉中5株(7%),458株耐多药且耐贝达喹啉中32株(7%),24株XDR中24株(100%)。
- 贝达喹啉耐药患病率从2016年3%升至2021年14%;聚类率(12个单核苷酸多态性阈值)在耐利福平菌株为42%,耐多药菌株为78%,pre-XDR菌株为94%,XDR菌株为96%。
- 704株中31株(4%)属于先前在埃斯瓦蒂尼描述的诊断逃逸暴发菌株(group_56),携带Xpert MTB/RIF无法检出的rpoB Ile491Phe突变(无其他rpoB突变);其中23株(74%)额外耐贝达喹啉,13株(42%)耐贝达喹啉和氟喹诺酮,2株(6%)耐贝达喹啉、氟喹诺酮和德拉马尼。
临床怎么用
- 作者认为,基于现有诊断流程和治疗方案,Ile491Phe所致利福平耐药和贝达喹啉耐药的出现可能危及耐多药结核的预防和诊疗,除非推广基于测序的技术。
- 作者指出,诊断逃逸菌株的潜在跨境传播需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2021, an estimated 4800 people developed rifampicin-resistant tuberculosis in Mozambique, 75% of which went undiagnosed. Detailed molecular data on rifampicin-resistant and multidrug-resistant (MDR) tuberculosis are not available. Here, we aimed at gaining precise data on the determinants of rifampicin-resistant and MDR tuberculosis in Mozambique. METHODS: In this retrospective observational study, we performed whole-genome sequencing of 704 rifampicin-resistant Mycobacterium tuberculosis complex (Mtbc) strains submitted to the National Tuberculosis Reference Laboratory (NTRL) in Maputo, Mozambique, between 2015 and 2021. Phylogenetic strain classification, genomic resistance prediction, and cluster analysis were performed. FINDINGS: Between Jan 1, 2015, and July 31, 2021, 2606 Mtbc isolates with an isoniazid or rifampicin resistance were identified in the NTRL biobank, of which, 1483 (56·9%) were from men, 1114 (42·7%) from women, and nine (0·4%) were unknown. Genome-based drug-resistant prediction classified 704 Mtbc strains as rifampicin resistant. 628 (89%) of the 704 Mtbc strains were classified MDR; of those, 146 (23%) were pre-extensively drug resistant (pre-XDR; additional fluoroquinolone resistance), and 24 (4%) extensively drug resistant (XDR; combined fluoroquinolone and bedaquiline resistance). Overall, 61 (9%) of 704 strains revealed resistance to bedaquiline: five (7%) of 76 rifampicin resistant plus bedaquiline resistant, 32 (7%) of 458 MDR plus bedaquiline resistant, and 24 (100%) of 24 XDR. Prevalence of bedaquiline resistance increased from 3% in 2016 to 14% in 2021. The cluster rate (12 single-nucleotide polymorphism threshold) was 42% for rifampicin-resistant strains, 78% for MDR strains, 94% for pre-XDR strains, and 96% for XDR Mtbc strains. 31 (4%) of 704 Mtbc strains, belonging to a diagnostic escape outbreak strain previously described in Eswatini (group_56), had an rpoB Ile491Phe mutation which is not detected by Xpert MTB/RIF (no other rpoB mutation). Of these, 23 (74%) showed additional resistance to bedaquiline, 13 (42%) had bedaquiline and fluoroquinolone resistance, and two (6%) were bedaquiline, fluoroquinolone, and delamanid resistant. INTERPRETATION: Pre-XDR resistance is highly prevalent among MDR Mtbc strains in Mozambique and so is bedaquiline resistance; and the frequency of bedaquiline resistance quadrupled over time and was found even in Mtbc strains without fluoroquinolone resistance. Importantly, strains with Ile491Phe mutation were frequent, accounting for 31% (n=10) of MDR plus bedaquiline-resistant strains and 54% (n=13) of XDR Mtbc strains. Given the current diagnostic algorithms and treatment regimens, both the emergence of rifampicin resistance due to Ile491Phe and bedaquiline resistance might jeopardise MDR tuberculosis prevention and care unless sequencing-based technology is rolled out. The potential cross border spread of diagnostic escape strains needs further investigation. FUNDING: The German Ministry of Health through the Seq_MDRTB-Net project, the Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy Precision Medicine in Inflammation and the Research Training Group 2501 TransEvo, the Leibniz Science Campus Evolutionary Medicine of the Lung, and the German Ministry of Education and Research via the German Center for Infection Research.
引用
- Barilar I, Fernando T, Utpatel C, et al. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study. Lancet Infect Dis. 2023. PMID: 37956677. doi:10.1016/S1473-3099(23)00498-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。